Menu Search
Equities

Enovis Corp

0I1B:LSE

Enovis Corp

Actions
  • Price (USD)46.79
  • Today's Change0.00 / 0.00%
  • Shares traded49.00
  • 1 Year change-3.18%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024 17:38 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.

  • Revenue in USD (TTM)2.00bn
  • Net income in USD-121.38m
  • Incorporated1998
  • Employees6.55k
  • Location
    Enovis Corp2711 CENTERVILLE ROAD, SUITE 400WILMINGTON 19808United StatesUSA
  • Phone+1 (302) 252-9160
  • Fax+1 (301) 323-9001
  • Websitehttps://www.enovis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.